



For immediate release, *November 21, 2013*

## **Genovis publish a new share issue prospectus**

Finansinspektionen (the Swedish Financial Supervisory Authority) approved on November 20 Genovis prospectus for 2013.

Genovis AB (publ)

The Board of Directors

For additional information please contact:

Sarah Fredriksson, CEO of Genovis AB

Tel: +46 (0)46-10 12 35

e-mail: [sarah.fredriksson@genovis.com](mailto:sarah.fredriksson@genovis.com)

### **ABOUT GENOVIS**

Genovis' business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

*Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00*